Angiogenesis inhibitors not recommended for the treatment of melanoma
After studying the potential benefits and harms of angiogenesis inhibitor therapy in patients with melanoma, researchers determined that this treatment results in no significant improvement in overall survival (OS) and progression-free survival (PFS) and may increase the risk of adverse events.
Seven randomized controlled trials including 3185 patients with melanoma investigating angiogenesis inhibitor therapy were analyzed. No significant difference in OS or PFS between the treatment groups were found as well as no significant effect of angiogenesis inhibitor therapy on disease control or objective response.
A trial sequential analysis demonstrated that the sample side for disease control analysis was sufficient.
Use of angiogenesis inhibitor therapy also increased the risks of hypertension, neurological symptoms, and diarrhea.
Reference
Fu XL, Feng LP, Yu HR, et al. Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized controlled trials. Melanoma Res. 2022;doi: 10.1097/CMR.0000000000000812. Epub ahead of print. PMID: 35377859.
